First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
The CheckMate -73L phase 3 trial missed its primary endpoint of progression-free survival (PFS) in unresectable stage 3 non-small cell lung cancer (NSCLC), according to a May 10th statement from Bristol Myers Squibb (BMS).
In this trial, a total of 925 patients were randomly assigned to receive Opdivo (nivolumab) in combination with concurrent chemoradiotherapy (CCRT) followed by either Opdivo plus Yervoy (ipilimumab), Opdivo monotherapy, or CCRT followed by Imfinzi (durvalumab).
“Unfortunately, adding immunotherapy concurrently with definitive chemoradiation did not improve PFS outcomes in this setting,” Joe Fiore, Pharm.D., BMS vice president, global product lead, thoracic cancers, states in the press release.
Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, a type of immunotherapy that helps immune cells attack cancer. First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Currently, Opdivo is given as an intravenous (IV) infusion. The infusion takes 30 to 60 minutes and is given every 2 or 4 weeks. It is typically given at a hospital or infusion center. However, a potentially time-saving option may become available in the near future.
On May 6th, the FDA accepted the Biologics License Application (BLA) for a subcutaneous formulation of Opdivo. The BLA was based on the results from the CheckMate -67T phase 3 trial in which subcutaneous Opdivo was shown to have non-inferior efficacy and a consistent pharmacologic and safety profile when compared to the IV formulation in patients with renal cell carcinoma.
The BLA includes all of Opdivo’s previously approved indications for solid tumors in adults as monotherapy, monotherapy following completion of Opdivo + Yervoy, or in combination with chemotherapy or cabozantinib (Cabometyx, Cometriq).
A subcutaneous (an injection given under the skin) form of Opdivo “would provide patients and their physicians with a new option that delivers the same well-known benefits as IV Opdivo but with the improved convenience of an injection administered in three-to-five minutes rather than a 30-to-60-minute infusion,” Gina Fusaro, Ph.D., vice president, global program lead at BMS, said in a press release.
In an interview earlier this year, Fusaro explained that subcutaneous immunotherapy can be given outside of an infusion center. It conveniently also avoids the need for an infusion port, which requires surgical placement.
“We hope that this translates to less time away from work or a reduction in childcare or eldercare costs due to less time away from home,” Fusaro said. “Ultimately, it may mean more time for the activities that they enjoy with the people they love.”
If approved by the FDA, Opdivo would become the first PD-1 inhibitor with a subcutaneous option. The formula includes nivolumab plus hyaluronidase, an enzyme that improves the absorption of medications injected under the skin.
The FDA has assigned a target action date of February 28, 2025.
Chest X-rays Linked to Earlier Lung Cancer Detection and Improved Outcomes
April 7th 2025A new study in England shows a strong link between higher rates of chest x-ray referrals in general practice patients with symptoms, such as persistent cough, and earlier lung cancer diagnoses, along with improved outcomes.
Read More
Study Finds Adherence to Annual Lung Cancer Screening Linked to Higher Detection Rates
March 18th 2025Researchers found that adherence to the first and second annual screenings was 61% and 51%, respectively, with higher lung cancer detection rates observed in those who followed through on these screenings.
Read More
Regeneron Canada Reaches New Agreement Deal for Cancer Drug Libtayo
March 7th 2025The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in different provinces and territories will cover the drug's cost for patients, according to a news release by Regeneron Canada.
Read More
Study Explores Immunotherapy vs. Chemoimmunotherapy Decisions For Advanced Non-Small Lung Cancer
March 5th 2025The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more recent diagnosis and prior glucocorticoid/steroid use.
Read More